NCT04390399Phase 2Active not recruiting

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Study sponsor: ImmunityBio, Inc. · IBRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-10-13Actual
Enrollment · participants328Estimated
Source updated2026-11-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 31 Oct 2025. After: 13 Oct 2025.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview